Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of SHP465 in Children with ADHD
NCT03325894Phase 3Terminated
- Sponsor
- Takeda
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHP465 mixed amphetamine salts in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Jan 2018; status: terminated.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03325894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325894.